Bottom cards (Which this is) does not render the title text, so what you put here doesn't matter.

‘World’s biggest quango’: The history of NHS England and what its abolition may look like

Expansion of OpenSAFELY: What it means for GP patient data

Will mummy make it better? The curious case of mummified remedies in early modern medicine

What will it take to improve palliative care to give patients a 'meaningful choice'? 

Analysis and Opinion

# The news that impacts UK doctors

[Final guidance](https://www.nice.org.uk/guidance/gid-ta10778/documents/html-content-8) by the National Institute for Health and Care Excellence hasrecommended lisocabtagene maraleucel (also called liso-cel or Breyanzi) as an option for treating patients with large B-cell lymphoma when their cancer has either not responded to initial treatment or returned within 12 months. 

Personalised cell therapy treatment for lymphoma given NICE approval

Log in or join for free to read more

You might also like